Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 7, 2003, Pages 3082-3089

  Kolterman, Orville G ^a   Buse, John B ^b   Fineman, Mark S ^a   Gaines, Eling ^a   Heintz, Sonja ^a   Bicsak, Thomas A ^a   Taylor, Kristin ^a   Kim, Dennis ^a   Aisporna, Maria ^a   Wang, Yan ^a   Baron, Alain D ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON; GLUCOSE; INSULIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STOMACH EMPTYING; VOMITING;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GASTRIC EMPTYING; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; TRIGLYCERIDES; VENOMS;

EID: 0038497464     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021545     Document Type: Article

References (49)

1. Kahn SE, Porte Jr D 1997 Pathophysiology of type II diabetes mellitus. In: Porte Jr D, Sherwin RS, eds. Diabetes mellitus, ed 5. Stamford, CT: Appleton and Lange; 487-512
2. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS 1999 Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22:403-408
3. Inzucchi SE 2002 Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-372
4. UK Prospective Diabetes Study Group 1995 UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258
5. UK Prospective Diabetes Study Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes (UKPDS 33). Lancet 352:837-853
6. Arner P, Pollace T, Lithell H 1991 Different etiologies of type 2 (non-insulin dependent) diabetes mellitus in obese and non obese subjects. Diabetologia 34:483-487
7. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, UKPDS Study Group 2002 Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330-336
8. Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
9. Frias JP, Yu JG, Kruszynska YT, Olefsky JM 2000 Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23:64-69
10. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP 2002 Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803
11. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M 2002 Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 15:2072-2077
12. Bhavsar S, Lachappell R, Watkins J, Young A 1998 Comparison of glucose-lowering effects of exendin-4 and GLP-1 in diabetic db/db mice. Diabetes 47:192A (Abstract)
13. Egan JM, Clocquet AR, Elahi D 2002 The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282-1290
14. Parkes DG, Pittner R, Jodka C, Smith P, Young A 2001 Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50:583-589
15. Gedulin B, Jodka C, Hoyt J 1999 Exendin-4 (AC2993) decreases glucagon secretion during hyperglycemic clamps in diabetic fatty Zucker rats. Diabetes 48:A199 (Abstract)
16. Jodka C, Gedulin B, Young A 1998 Exendin-4 potently regulates gastric emptying in rats. Diabetes 47:403A (Abstract)
17. Rayner CK, Samsom M, Jones KL, Horowitz M 2001 Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 24:371-381
18. Bhavsar S, Watkins J, Young A 1998 Comparison of central and peripheral effects of exendin-4 and GLP-1 on food intake in rats. Program and Abstracts of the 80th Annual Meeting of The Endocrine Society, New Orleans, LA, p 433 (Abstract)
19. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM 2000 Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941
20. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B 1993 Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655
21. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM 1999 Once daily iniection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42:45-50
22. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M 1999 Glucose-lowering and insulin-sensitizing actions of exendin-4. Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic Rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034
23. Gedulin B, Lawler R, Jodka C, Young A 1997 Amylin inhibits pentagastrin-stimulated gastric acid secretion: comparison with glucagon-like peptide-1 and exendin-4. Diabetes 46:188A (Abstract)
24. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, Uchida K 2000 The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 80:14-21
25. Xu G, Stoffers DA, Habener JF, Bonner-Weir S 1999 Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276
26. Tourrel C, Bailbé D, Meile M-J, Kergoat M, Portha B 2001 Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50:1562-1570
27. Tourrel C, Bailbé D, Lacorne M, Meile MJ, Kergoat M, Portha B 2002 Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51:1443-1452
28. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA 2002 Lack of effect of exendin-4 and glucagon-like peptide-1-(7, 36)-amide on insulin action in non-diabetic humans. Diabetologia 45:1410-1415
29. Buse J, Fineman M, Gottlieb A, Gaines E, Kolterman O 2000 Effects of five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes. Diabetes 49:A100 (Abstract)
30. Kolterman O, Gottlieb A, Gaines E, Fineman M 2000 Five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes reduces post-prandial glucose, glucagon and triglyceride concentrations. Diabetologia 43:A189 (Abstract)
31. Kim D, Taylor K, Bicsak T, Wang Y, Aisporna M, Heintz S, Fineman MS, Baron A 2002 Subcutaneous injection of AC2993 (synthetic exendin-4) lowered fasting glucose concentrations through suppression of glucagon and dose dependent insulinotropism in patients with type 2 diabetes. Diabetes 51:A104 (Abstract)
32. Clements JA, Heading RC, Nimmo WS, Prescott LF 1978 Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther 24:420-431
33. Peterson JI, Young DS 1968 Evaluation of the hexokinase-glucose-6-phosphate dehydrogenase method of determination of glucose in urine. Anal Biochem 1968 23:301-316
34. Schmidt FH 1973 Blood glucose levels in capillary blood of adults assessed by the hexokinase method. Klin Wochenschr 51:520-522
35. Young A, Blase E, Petrella E, Seward M 1999 Exendin-4 is a circulating meal-related peptide in the Gila monster (Heloderma suspectum). Diabetes 48(Suppl 1):A425
36. Chen YE, Drucker D 1997 Tissue-specific expression of unique mRNAs that encode pro-glucagon-derived peptides or exendin-4 in the lizard. J Biol Chem 272:4108-4115
37. Drucker DJ 1998 Glucagon-like peptides. Diabetes 47:159-169
38. Henquin J-C 2000 Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-1760
39. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A 2001 Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 53:260-267
40. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB 1987 Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106-110
41. Baron AD, Schaeffer L, Shragg P, Kolterman OG 1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283
42. Mahler RJ, Adler ML 1999 Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 84:1165-1171
43. Moore MC, Cherrington AD 1996 Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms. Reprod Nutr Dev 36:399-406
44. Green GM, Guan D, Schwartz JG, Phillips WT 1997 Accelerated gastric emptying of glucose in Zucker type 2 diabetic rats: role in postprandial hyperglycaemia. Diabetologia 40:136-142
45. Harju E, Nordback I 1987 Postprandial hyperglycemia after different carbohydrates in patients with total gastrectomy. Surg Gynecol Obstet 165:41-45
46. MacGregor IL, Gueller R, Watts HD, Meyer JH, MacGregor IL, Gueller R, Watts HD, Meyer JH 1976 The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology 70:190-196
47. Moyses C, Young A, Kolterman O 1996 Modulation of gastric emptying as a therapeutic approach to glycaemic control. Diabetic Med 13:S34-S38
48. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
49. Nauck MA, Sauerwald A, Ritzel R 1998 Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21:1925-1931